Dexcom (Nasdaq: DXCM) has shared a new report highlighting access and attitudes toward type 2 diabetes in the U.S.
Our sister site, Drug Delivery Business News, reports today that the company released a new report, titled “Dexcom State of Type 2 Report: Access and Attitudes Across the United States.”
Dexcom released its report ahead of the American Diabetes Association’s 85th Scientific Sessions in Chicago. Findings provide insights into perceptions around diabetes technology from more than 400 healthcare professionals and people with type 2 diabetes across the U.S.
San Diego-based Dexcom develops continuous glucose monitoring (CGM) and biosensing technologies. It aims to bring the technology to more people, especially within the diabetes community.
The company earlier this year launched a similar report covering Europe and the Middle East. President and COO Jake Leach spoke to Drug Delivery Business News about the significance of that report in March. The company says the latest report builds on those initial findings with data collected in the U.S.
Get the full story at our sister site, Drug Delivery Business News.
